Instruments

Name Stock exchange Average volume Price Type
GEORGE WESTON LIMITED WN.PR.C

Toronto S.E. +2 Other

4,260 20.75 CAD Stock George Weston Limited Stock
GEORGE WESTON LIMITED WNGP.F

OTC Markets

0 14.19 CAD Stock George Weston Limited
GEORGE WESTON LIMITED WNGPF

OTC Markets

1 13.95 USD Stock George Weston Limited
GEORGE WESTON LIMITED WN.PR.A

Toronto S.E. +1 Other

6,377 22.91 CAD Stock George Weston Limited Stock
GEORGE WESTON LIMITED WGEGF

OTC Markets

- - USD Stock George Weston Limited
GEORGE WESTON LIMITED WN.PR.D

Toronto S.E.

5,475 20.75 CAD Stock George Weston Limited Stock
GEORGE WESTON LIMITED WN.PR.E

Toronto S.E.

2,622 19.16 CAD Stock George Weston Limited Stock
GEORGE WESTON LIMITED WN

Toronto S.E. +3 Other

116,724 194.8 CAD Stock George Weston Limited Stock
GEORGE WESTON LIMITED WX5

Deutsche Boerse AG

- 130 EUR Stock George Weston Limited
GEORGE WESTON LIMITED WX5

BOERSE MUENCHEN

- 131 EUR Stock George Weston Limited
GEORGE WESTON LIMITED WNGRF

OTC Markets

5,425 141.8 USD Stock George Weston Limited
GEORGE KENT (MALAYSIA) GKENT

BURSA MALAYSIA

720,013 0.49 MYR Stock George Kent (Malaysia) Stock
ST GEORGE MINING LIMITED SGQ

Australian S.E. +1 Other

887,952 0.017 AUD Stock St George Mining Limited Stock
ST GEORGE MINING LIMITED S0G

Deutsche Boerse AG

- 0.006 EUR Stock St George Mining Limited
GEORGE RISK INDUSTRIES, INC. RSKIA

OTC Markets

672 12.85 USD Stock George Risk Industries, Inc. Stock
RSE ARCHIVE LLC - MEMBERSHIP INTERESTS SERIES - 1780 GEORGE WASHINGTON LETTER FUND RGWLS

OTC Markets

0 - USD Stock Rse Archive LLC - Membership Interests Series - 1780 George Washington Letter Fund Stock

News (380)

Transcript : Voyager Therapeutics, Inc., Q2 2023 Earnings Call, Aug 03, 2023
Voyager Therapeutics Reports Second Quarter 2023 Financial and Operating Results AQ
Transcript : Voyager Therapeutics, Inc., Q1 2023 Earnings Call, May 09, 2023
VOYAGER THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K) AQ
Voyager Therapeutics Reports First Quarter 2023 Financial and Operating Results AQ
Voyager Therapeutics Announces Appointment of George Scangos, Ph.D., to Board of Directors AQ
Voyager Therapeutics, Inc. Appoints George Scangos as Director and as Member of Science and Technology Committee CI
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results GL
AGILENT TECHNOLOGIES, INC. : Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K) AQ
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results GL
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results AQ
Vir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK's National Institute for Health and Care Excellence AQ
Vir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK’s National Institute for Health and Care Excellence (NICE) GL
Vir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK’s National Institute for Health and Care Excellence (NICE) AQ
Vir Biotechnology Appoints Sung Lee as Chief Financial Officer GL
Vir Biotechnology Appoints Sung Lee as Chief Financial Officer AQ
Vir Biotechnology Announces Amended Collaboration Agreement with GSK GL
Vir Biotechnology Announces Amended Collaboration Agreement with GSK GL
VIR BIOTECHNOLOGY, INC. : Change in Directors or Principal Officers (form 8-K) AQ
Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor GL
Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor AQ
Vir Biotechnology, Inc. Announces CEO Changes CI
Transcript : Vir Biotechnology, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-10-2023 09:45 AM
Vir Biotechnology to Highlight Anticipated 2023 Catalysts and Long-Term Growth Strategy at 41st Annual J.P. Morgan Healthcare Conference GL
Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500 AQ
Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™ GL
Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™ AQ
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2022 Financial Results GL
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2022 Financial Results AQ
Vir Biotech gets U.S. funding for flu-prevention antibody RE
Vir Biotechnology : Provides Corporate Update and Reports Second Quarter 2022 Financial Results - Form 8-K PU
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2022 Financial Results GL
Vir Biotechnology Announces Transition of Chief Scientific Officer GL
Vir Biotechnology Announces Transition of Chief Scientific Officer GL
VIR BIOTECHNOLOGY, INC. : Submission of Matters to a Vote of Security Holders (form 8-K) AQ
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Results GL
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Results AQ
Transcript : Vir Biotechnology, Inc. - Special Call
Vir Biotechnology Announces New Data From the MARCH Hepatitis B Trial, Unveils New Hepatitis D Clinical Program and Highlights Broad Hepatitis Portfolio at Virtual Hepatitis Portfolio R&D Day GL
Vir Biotechnology Announces New Data From the MARCH Hepatitis B Trial, Unveils New Hepatitis D Clinical Program and Highlights Broad Hepatitis Portfolio at Virtual Hepatitis Portfolio R&D Day GL
Vir Biotechnology to Host a Virtual Hepatitis Portfolio R&D Day AQ
Vir Biotechnology Scientists Named Winners of the BARDA and HHS-Sponsored Pediatric COVID-19 Data Challenge GL
AGILENT TECHNOLOGIES, INC. : Submission of Matters to a Vote of Security Holders (form 8-K) AQ
Vir Biotechnology : Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results - Form 8-K PU
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results AQ
1234NextSee all

Companies (55)

GEORGE WESTON LIMITED 18 851 M $
Logo George Weston Limited

George Weston Limited is a Canada-based company. The Company operates through two segments: Loblaw Companies Limited (Loblaw) and Choice Properties Real Estate Investment Trust (Choice Properties). Loblaw has two reportable operating segments, retail and ...

PERNOD RICARD 39 423 M $
Logo Pernod Ricard

Pernod Ricard is the world's No. 2 in the production and marketing of Premium and Prestige spirits and wines. Net sales break down by family of products as follows: - spirits and champagnes of strategic international brands (63.4%): Absolut (12.7 million ...

TAYLOR WIMPEY PLC 6 533 M $
Logo Taylor Wimpey plc

Taylor Wimpey plc is one of the leading British home builders. Net sales break down by activity as follows: - construction and sale of homes (98.7%): activity assured in the United Kingdom (George Wimpey, G2, Wilson Connolly and Laing Homes brands), Nort ...

GEORG FISCHER AG 6 197 M $
Logo Georg Fischer AG

Georg Fischer AG is a Switzerland-based company engaged in the development of systems for industrial applications. The Company operates through three business segments: GF Piping Systems, GF Casting Solutions, and GF Machining Solutions. GF Piping Systems ...

THE BERKELEY GROUP HOLDINGS PLC 7 051 M $
Logo The Berkeley Group Holdings plc

The Berkeley Group Holdings plc is a United Kingdom-based company engaged in building homes and neighborhoods across London, Birmingham, and the South of England. The Company and its subsidiaries are engaged in residential-led, mixed-use property developm ...

THE GPT GROUP 5 558 M $
Logo The GPT Group

The GPT Group is an Australia-based vertically integrated diversified property company that owns and actively manages a portfolio of Australian retail, office and logistics assets, with assets under management of approximately $32.2 billion. The Company u ...

IRIS ENERGY LIMITED 1 095 M $
Logo Iris Energy Limited

Iris Energy Limited is an Australia-based sustainable Bitcoin mining company that supports the decarbonization of energy markets and the global Bitcoin network. It owns and operates Bitcoin mining data centers powered by 100% renewable energy. The Company ...

RESOLUTION MINERALS LTD 3 M $
Logo Resolution Minerals Ltd

Resolution Minerals Ltd is an Australia-based mineral exploration company engaged in the acquisition, exploration, and development of precious and battery metals, such as gold, copper, cobalt, and uranium. The Company's projects include 64North Project, G ...

MT MALCOLM MINES NL 2 M $
Logo Mt Malcolm Mines NL

Mt Malcolm Mines NL is an Australia-based gold focused exploration company. The Company’s project includes the Mt Malcolm Gold Project. Its project is divided into nine major prospect areas, which include Mt George, Emu Egg, Germatong and Rabbit Warren ...

HERCULES RESOURCES CORP. 5 M $
Logo Hercules Resources Corp.

Hercules Resources Corp. is a Canada-based mineral exploration company. The Company is involved in the exploration and development of mineral properties located in British Columbia. The Company’s sole mineral project is the MP Copper Project, which is l ...


1234Next

Insiders

Picture George Scangos
George Scangos

George A. Scangos is a businessperson who has been the head of 10 different companies and currently occupies the position of President, Chief Executive Officer & Director at Vir Biotechnology, Inc. He is also Member-National Board of Visitor at the University of California and on the board of 5 other companies. In his past career George A. Scangos held the position of Director at Decibel Therapeutics, Inc., Chief Executive Officer & Director at Biogen, Inc. Chief Executive Officer at Biogen Idec New Ventures, Inc. and Chief Executive Officer of Biogen Idec, Inc. (North Carolina) (both are subsidiaries of Biogen, Inc.), President, Chief Executive Officer & Director at Exelixis, Inc., President for Bayer Biotechnology, Chairman of Anadys Pharmaceuticals, Inc., Chairman of California Healthcare Institute, Senior Vice President-Research & Development at Bayer, Inc., President-Biotechnology Division at Bayer Corp., Chairman for Pharmaceutical Research & Manufacturers of America and Professor at The Johns Hopkins University. He received a doctorate from the University of Massachusetts and an undergraduate degree from Cornell University.



Picture George Milton George
George Milton George

George Milton George worked as a Chief Financial Officer at Middle East Paper Co.





Picture George Muthoot George
George Muthoot George

George Muthoot George is currently the Executive Director & Co-Deputy MD at Muthoot Finance Ltd.
He is also a Director at Muthoot Broadcasting Pvt Ltd., Muthoot Securities Ltd., Muthoot Insurance Brokers Pvt Ltd., Muthoot Anchor House Hotels Pvt Ltd., Muthoot Holidays Pvt Ltd., and Patgaon Plantations Pvt Ltd.
Additionally, he holds the position of Managing Director at Xandari Pearl Beach Resorts Pvt Ltd.
and Muthoot Leisure & Hospitality Services Pvt Ltd.
In terms of education, Mr. George is a graduate of ESSEC Business School and holds an undergraduate degree from Welcomgroup Graduate School of Hotel Administration.


Picture George Muthoot George
George Muthoot George

George Muthoot George currently works as a Director at Muthoot Securities Ltd.

No results for this search